AMPH

Business Context and Reporting Period

Company: Amphastar Pharmaceuticals, Inc. (AMPH)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Amphastar is a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Key products include BAQSIMI (glucagon nasal powder), Primatene MIST, and various injectable generics. The company operates manufacturing facilities in the U.S., France, and China.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total net revenues decreased 2% primarily due to the elimination of "Other revenues" ($19.2 million in 2024) related to BAQSIMI sales managed by Eli Lilly under a Transition Service Agreement (TSA). In 2025, Amphastar assumed full distribution responsibility, moving all BAQSIMI revenue to "Product revenues, net."
• Product Mix Shifts:
  • BAQSIMI: Sales increased 46% ($185.4M) as the company took over global distribution.
  • Glucagon: Sales decreased 36% ($69.1M) due to lower average selling prices and volume shifts to ready-to-use products like BAQSIMI.
  • Epinephrine: Sales decreased 25% ($70.6M) due to increased competition and lower pricing.
  • Primatene MIST: Sales increased 7% ($108.7M) driven by volume growth.
• Expense Increases:
  • General & Administrative (G&A): Increased 51% to $85.9 million, primarily driven by a $23.1 million legal settlement related to a personal injury lawsuit.
  • Research & Development (R&D): Increased 16% to $85.8 million, largely due to a $6.0 million upfront payment for a licensing agreement with Nanjing Anji Biotechnology.
• Profitability: Net income declined 38% to $98.1 million, impacted by the legal settlement, increased R&D spend, and lower gross margins from pricing pressures on legacy products.

Guidance, Outlook, and Risks

• Recent Approvals & Launches:
  • August 2025: FDA approved Iron Sucrose Injection (launched Q3 2025).
  • December 2025: FDA approved Teriparatide Injection (launched December 2025).
  • February 2026: FDA approved Ipratropium Bromide HFA inhalation aerosol (planned launch Q2 2026).
• Strategic Outlook: Management expects continued investment in R&D for insulin biosimilars and proprietary products. The company anticipates sales of legacy glucagon products will continue to decline due to competitive dynamics.
• Key Risks:
  • Supply Chain: Reliance on single-source suppliers for certain APIs and Contract Manufacturing Organizations (CMOs) for BAQSIMI.
  • Regulatory: Risks associated with FDA inspections, the AIM Act (hydrofluorocarbon restrictions affecting inhalation products), and potential trade tariffs impacting imports from China.
  • Debt: Significant indebtedness ($610.4M) including a $345M Convertible Note due 2029 and a $250M Term Loan due 2028, subject to restrictive covenants.
  • Legal: Ongoing employment litigation (PAGA claims) and potential product liability exposures.

Investor Verification Checklist

• BAQSIMI Transition: Verify the full integration of BAQSIMI supply chain and sales operations post-TSA completion in 2025.
• Legal Settlement Impact: Confirm the finality of the $23.1 million personal injury settlement and assess potential for future product liability claims.
• Debt Covenants: Review compliance with financial covenants (leverage and interest coverage ratios) under the Wells Fargo Credit Agreement and Convertible Note indenture.
• Legacy Product Decline: Monitor the rate of revenue erosion in Glucagon and Epinephrine multi-dose vials versus growth in new launches (Iron Sucrose, Teriparatide).
• China Operations: Assess exposure to geopolitical risks, tariffs, and regulatory changes affecting the Nanjing manufacturing facility.